Chromosomal Crossover News and Research

RSS

MSU research pushes promising molecule toward clinical trials for treatment of neurological disorders

The most effective way to tackle debilitating diseases is to punch them at the start and keep them from growing.

22 Apr 2014

Study finds ginseng can help prevent, treat influenza and RSV infection

Ginseng can help treat and prevent influenza and respiratory syncytial virus (RSV), a respiratory virus that infects the lungs and breathing passages, according to research findings by a scientist in Georgia State University's new Institute for Biomedical Sciences.

22 Apr 2014

IV-administered ketamine effective in patients with chronic PTSD

For the first time, evidence that a single dose of IV-administered ketamine was associated with the rapid reduction of symptoms of post-traumatic stress disorder in patients with chronic PTSD was demonstrated in a proof-of-concept, randomized, double blind crossover study, undertaken by researchers at the Icahn School of Medicine at Mount Sinai in New York City. These findings, according to Mount Sinai researchers, could be the first step toward developing new interventions for PTSD.

21 Apr 2014

Adocia announces positive results from BioChaperone Lispro phase IIa clinical trial

Adocia announces positive results from a phase IIa clinical trial evaluating its innovative ultra-fast formulation of insulin Lispro in comparison to Eli Lilly’s Humalog commercial insulin. Adocia’s formulation incorporates proprietary BioChaperone technology which enables accelerated absorption of prandial insulins. Humalog, which is now off-patent, has annual sales of USD 2.6 billion.

10 Apr 2014

Study shows dabrafenib has no added benefit in comparison with dacarbazine

Dabrafenib (trade name: Tafinlar) has been approved since August 2013 for the treatment of advanced melanoma. In January 2014, in an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) had determined that dabrafenib has no added benefit in comparison with dacarbazine.

10 Apr 2014

Intranasal ketamine spray confers rapid antidepressant effect in patients with depressive disorder

A research team from the Icahn School of Medicine at Mount Sinai published the first controlled evidence showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect -within 24 hours-and was well tolerated in patients with treatment-resistant major depressive disorder.

9 Apr 2014

Neurovance closes $6.3M extension to its series A1 financing round to advance development of EB-1020 SR

Neurovance, Inc. today announced that it has closed a $6.3 million extension to its series A1 financing round to further advance development of EB-1020 SR, a non-stimulant, for the treatment of all subtypes of adult ADHD (attention deficit hyperactivity disorder).

3 Apr 2014

CardioCell receives IND approval for Phase IIa clinical study of itMSC therapy to treat heart failure

CardioCell LLC has just received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with chronic heart failure (CHF), which generates more than 1 million hospitalizations annually.

3 Apr 2014

BIO and WLSA to explore intersection between digital health and biotechnology at 2014 BIO International Convention

The Biotechnology Industry Organization (BIO) and the Wireless-Life Sciences Alliance (WLSA) today announced a partnership to explore the intersection between digital health and biotechnology through the inaugural Digital Health Zone and Forum at the 2014 BIO International Convention®.

3 Apr 2014

ChromaDex declares full-year 2013 financial results

ChromaDex® Corp., an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the year ended December 28, 2013.

27 Mar 2014

People eat more breakfast cereal when flake size is reduced, say researchers

People eat more breakfast cereal, by weight, when flake size is reduced, according to Penn State researchers, who showed that when flakes are reduced by crushing, people pour a smaller volume of cereal into their bowls, but still take a greater amount by weight and calories.

27 Mar 2014

Shimadzu announces FDA approval for new digital angiography systems

Shimadzu Medical Systems USA has announced that a new digital angiography system family has received 510(k) clearance from the U.S. Food and Drug Administration. These are the ceiling-mounted Trinias, the floor-mounted Trinias, and the Biplane models.

27 Mar 2014

Adocia announces positive final results for first clinical trial of BioChaperone Combo

Adocia announces today positive final results for the first clinical trial on its innovative formulation combining insulin analog glargine (Lantus, Sanofi), the gold standard basal insulin, with a rapid-acting insulin analog, lispro (Humalog, Eli Lilly) using Adocia's BioChaperone technology.

20 Mar 2014

New pilot study shows little difference in digestibility between raw milk and pasteurized milk

Some sour news for lactose-intolerant people who hoped that raw milk might prove easier to stomach than pasteurized milk: A pilot study from the Stanford University School of Medicine shows little difference in digestibility between the two.

11 Mar 2014

Scientists develop new nasal filter that helps people with nasal symptoms from seasonal hay fever

A small filter the size of a contact lens could possibly make life easier for some of the estimated 500 million people worldwide who suffer from itching, sneezing and a runny nose as soon as the pollen season starts.

10 Mar 2014

Outbursts of anger may trigger heart attacks and strokes, shows study

Outbursts of anger may trigger heart attacks, strokes and other cardiovascular problems in the two hours immediately afterwards, according to the first study to systematically evaluate previous research into the link between the extreme emotion and all cardiovascular outcomes.

4 Mar 2014

Angry outbursts increase heart attack risk

Call it what you will - getting red in the face, hot under the collar, losing your cool, blowing your top - we all experience anger. And while we know that anger is a normal, sometimes even beneficial emotion, we're also aware of the often harmful connection between anger and health. New research from Beth Israel Deaconess Medical shows an even more compelling reason to think about getting anger in check - a nearly fivefold increase in risk for heart attack in the two hours following outbursts of anger.

4 Mar 2014

Adocia reports positive preliminary results for first clinical trial of BioChaperone Combo

Adocia announces today positive preliminary results for the first clinical trial on an innovative formulation combining insulin analog Glargine (Lantus, Sanofi), the gold standard basal insulin, with a rapid-acting insulin analog, Lispro (Humalog, Eli Lilly) using Adocia's BioChaperone technology.

27 Feb 2014

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.

26 Feb 2014

Origin of deadly human malaria parasite linked to primates in Africa, not Asia

An international team of scientists has traced the origin of Plasmodium vivax, the second-worst malaria parasite of humans, to Africa, according to a study published this week in Nature Communications.

25 Feb 2014

Chromosomal Crossover News and Research

MSU research pushes promising molecule toward clinical trials for treatment of neurological disorders

Study finds ginseng can help prevent, treat influenza and RSV infection

IV-administered ketamine effective in patients with chronic PTSD

Adocia announces positive results from BioChaperone Lispro phase IIa clinical trial

Study shows dabrafenib has no added benefit in comparison with dacarbazine

Intranasal ketamine spray confers rapid antidepressant effect in patients with depressive disorder

Neurovance closes $6.3M extension to its series A1 financing round to advance development of EB-1020 SR

CardioCell receives IND approval for Phase IIa clinical study of itMSC therapy to treat heart failure

BIO and WLSA to explore intersection between digital health and biotechnology at 2014 BIO International Convention

ChromaDex declares full-year 2013 financial results

People eat more breakfast cereal when flake size is reduced, say researchers

Shimadzu announces FDA approval for new digital angiography systems

Adocia announces positive final results for first clinical trial of BioChaperone Combo

New pilot study shows little difference in digestibility between raw milk and pasteurized milk

Scientists develop new nasal filter that helps people with nasal symptoms from seasonal hay fever

Outbursts of anger may trigger heart attacks and strokes, shows study

Angry outbursts increase heart attack risk

Adocia reports positive preliminary results for first clinical trial of BioChaperone Combo

FDA approves KALYDECO for people with cystic fibrosis

Origin of deadly human malaria parasite linked to primates in Africa, not Asia

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News